{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:49:56Z","timestamp":1789678196460,"version":"4.0.1"},"reference-count":53,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"unspecified","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016627","name":"Anticancer Fund","doi-asserted-by":"publisher","award":["RCT-A80-2021"],"award-info":[{"award-number":["RCT-A80-2021"]}],"id":[{"id":"10.13039\/100016627","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015652","name":"Barts Charity","doi-asserted-by":"publisher","award":["MGU0598"],"award-info":[{"award-number":["MGU0598"]}],"id":[{"id":"10.13039\/100015652","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023262","name":"Jon Moulton Charity Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023262","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,11,22]]},"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n<jats:title>Introduction<\/jats:title>\n<jats:p>Adaptive ChemoTherapy for Ovarian cancer (ACTOv) is a phase II, multicentre, randomised controlled trial, evaluating an adaptive therapy (AT) regimen with carboplatin in women with relapsed, platinum-sensitive high-grade serous or high-grade endometrioid cancer of the ovary, fallopian tube and peritoneum whose disease has progressed at least 6 months after day 1 of the last cycle of platinum-based chemotherapy. AT is a novel, evolutionarily informed approach to cancer treatment, which aims to exploit intratumoral competition between drug-sensitive and drug-resistant tumour subpopulations by modulating drug dose according to a patient\u2019s own response to the last round of treatment. ACTOv is the first clinical trial of AT in this disease setting.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods and analysis<\/jats:title>\n<jats:p>80 patients will be randomised 1:1 to standard therapy (control) or AT (investigational) arms. The starting and maximum carboplatin dose in both arms is area under the curve (AUC) \u00d75 according to absolute nuclear medicine glomerular filtration rate. The AT regimen will modify the carboplatin dose according to changes in the serum biomarker CA125, a proxy measure of total tumour burden. Patients will receive treatment intravenously every 21 days for a maximum of 6 and 12 cycles in the control and investigational arms, respectively. The primary endpoint is modified progression-free survival (investigator-assessed using RECIST 1.1 (Response Evaluation Criteria in Solid Cancers) compared with the baseline prerandomisation scan rather than the radiological nadir), clinical progression or death from any cause. Secondary endpoints will include acceptability, deliverability, compliance, toxicity, CA125, quality of life and overall survival. ACTOv is open to National Health Service hospitals throughout the UK, recruitment is anticipated to take 36 months across 10 sites and will be managed by the Cancer Research UK and University College London Cancer Trials Centre.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Ethics and dissemination<\/jats:title>\n<jats:p>The trial has been reviewed and received approval from the London\u2014Dulwich Research Ethics Committee (REC). Results of the trial will be disseminated through publication in peer-reviewed journals.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Trial registration number<\/jats:title>\n<jats:p>\n<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05080556\">NCT05080556<\/jats:ext-link>\n.\n<\/jats:p>\n<\/jats:sec>","DOI":"10.1136\/bmjopen-2024-091262","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T01:45:49Z","timestamp":1735004749000},"page":"e091262","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancer"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct05080556","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05393791","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05651828","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04388839","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06470880","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03543969","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6693-8788","authenticated-orcid":false,"given":"Uma Anne","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4509-6387","authenticated-orcid":false,"given":"Helen","family":"Hockings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0688-9192","authenticated-orcid":false,"given":"Nicholas","family":"Counsell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2096-4840","authenticated-orcid":false,"given":"Apini","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4343-6483","authenticated-orcid":false,"given":"Katie","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9870-6422","authenticated-orcid":false,"given":"Harjot","family":"Dhanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9387-7586","authenticated-orcid":false,"given":"Iain","family":"McNeish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2536-4383","authenticated-orcid":false,"given":"Alexander R A","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2400-1716","authenticated-orcid":false,"given":"Rowan","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2377-7221","authenticated-orcid":false,"given":"Charlie","family":"Gourley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9582-1597","authenticated-orcid":false,"given":"Trevor","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9281-5789","authenticated-orcid":false,"given":"Michelle","family":"Lockley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,12,22]]},"reference":[{"key":"2024122206361731000_14.12.e091262.1","unstructured":"Cancer Research UK . Ovarian cancer statistics. Available: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/ovarian-cancer [Accessed 2 Apr 2024]."},{"key":"2024122206361731000_14.12.e091262.2","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0b013e3181c042b6"},{"key":"2024122206361731000_14.12.e091262.3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz062"},{"key":"2024122206361731000_14.12.e091262.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62146-7"},{"key":"2024122206361731000_14.12.e091262.5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds203"},{"key":"2024122206361731000_14.12.e091262.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13718-X"},{"key":"2024122206361731000_14.12.e091262.7","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.307"},{"key":"2024122206361731000_14.12.e091262.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.7519"},{"key":"2024122206361731000_14.12.e091262.9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt406"},{"key":"2024122206361731000_14.12.e091262.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2003.08.017"},{"key":"2024122206361731000_14.12.e091262.11","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e3182049273"},{"key":"2024122206361731000_14.12.e091262.12","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3298"},{"key":"2024122206361731000_14.12.e091262.13","doi-asserted-by":"publisher","DOI":"10.1038\/459508a"},{"key":"2024122206361731000_14.12.e091262.14"},{"key":"2024122206361731000_14.12.e091262.15","doi-asserted-by":"publisher","DOI":"10.1038\/nrc4019"},{"key":"2024122206361731000_14.12.e091262.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0411-1"},{"key":"2024122206361731000_14.12.e091262.17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3658"},{"key":"2024122206361731000_14.12.e091262.18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-0806"},{"key":"2024122206361731000_14.12.e091262.19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2649"},{"key":"2024122206361731000_14.12.e091262.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2001110","article-title":"How to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient","volume":"15","author":"Hansen","year":"2017","journal-title":"PLoS Biol"},{"key":"2024122206361731000_14.12.e091262.21","doi-asserted-by":"publisher","DOI":"10.1038\/nature13121"},{"key":"2024122206361731000_14.12.e091262.22","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nm0715-827b","article-title":"Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients","volume":"21","author":"Siravegna","year":"2015","journal-title":"N Med"},{"key":"2024122206361731000_14.12.e091262.23","doi-asserted-by":"crossref","unstructured":"Hockings H , Lakatos E , Huang W , et al . Adaptive therapy achieves long-term control of chemotherapy resistance in high grade ovarian cancer. bioRxiv 2023. doi:10.1101\/2023.07.21.549688","DOI":"10.1101\/2023.07.21.549688"},{"key":"2024122206361731000_14.12.e091262.24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s43856-022-00110-x","article-title":"Spatial structure impacts adaptive therapy by shaping intra-tumoral competition","volume":"2","author":"Strobl","year":"2022","journal-title":"Commun Med (Lond)"},{"key":"2024122206361731000_14.12.e091262.25","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s41559-021-01428-w","article-title":"A theoretical analysis of tumour containment","volume":"5","author":"Viossat","year":"2021","journal-title":"Nat Ecol Evol"},{"key":"2024122206361731000_14.12.e091262.26","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a033415","article-title":"The Evolution and Ecology of Resistance in Cancer Therapy","volume":"8","author":"Gatenby","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2024122206361731000_14.12.e091262.27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2007066","article-title":"Is adaptive therapy natural?","volume":"16","author":"Thomas","year":"2018","journal-title":"PLoS Biol"},{"key":"2024122206361731000_14.12.e091262.28","first-page":"1878","article-title":"Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer","volume":"60","author":"Browder","year":"2000","journal-title":"Cancer Res"},{"key":"2024122206361731000_14.12.e091262.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0413-z"},{"key":"2024122206361731000_14.12.e091262.30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15092471","article-title":"Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors","volume":"15","author":"Muraro","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2024122206361731000_14.12.e091262.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.008"},{"key":"2024122206361731000_14.12.e091262.32","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad7842"},{"key":"2024122206361731000_14.12.e091262.33","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2235"},{"key":"2024122206361731000_14.12.e091262.34","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1038\/s41467-017-01516-1","article-title":"Spatial competition constrains resistance to targeted cancer therapy","volume":"8","author":"Bacevic","year":"2017","journal-title":"Nat Commun"},{"key":"2024122206361731000_14.12.e091262.35","doi-asserted-by":"publisher","DOI":"10.1038\/nature11814"},{"key":"2024122206361731000_14.12.e091262.36","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ebiom.2019.09.023","article-title":"Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma","volume":"48","author":"Smalley","year":"2019","journal-title":"EBioMedicine"},{"key":"2024122206361731000_14.12.e091262.37","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.cels.2024.04.003","article-title":"To modulate or to skip: De-escalating PARP inhibitor maintenance therapy in ovarian cancer using adaptive therapy","volume":"15","author":"Strobl","year":"2024","journal-title":"Cell Syst"},{"key":"2024122206361731000_14.12.e091262.38","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.76284","article-title":"Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes","volume":"11","author":"Zhang","year":"2022","journal-title":"Elife"},{"key":"2024122206361731000_14.12.e091262.39","unstructured":"Study details | Phase II randomised controlled trial of patient-specific adaptive vs. continuous abiraterone or enzalutamide in mcrpc (anzadapt). ClinicalTrials.gov. Available: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05393791#contacts [Accessed 1 May 2024]."},{"key":"2024122206361731000_14.12.e091262.40","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00793-8"},{"key":"2024122206361731000_14.12.e091262.41","unstructured":"Study details | Adaptive therapy of vismodegib in advanced basal cell carcinoma. ClinicalTrials.gov. Available: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05651828 [Accessed 1 May 2024]."},{"key":"2024122206361731000_14.12.e091262.42","unstructured":"Study details | evolutionary therapy for rhabdomyosarcoma. ClinicalTrials.gov. Available: https:\/\/clinicaltrials.gov\/study\/NCT04388839 [Accessed 1 May 2024]."},{"key":"2024122206361731000_14.12.e091262.43","unstructured":"Study details | Circulating tumour DNA guided adaptive BRAF and MEK inhibitor therapy (DyNAMIc). ClinicalTrials.gov. Available: https:\/\/clinicaltrials.gov\/study\/NCT06470880 [Accessed 4 Jul 2024]."},{"key":"2024122206361731000_14.12.e091262.44","unstructured":"Study details | adaptive BRAF-MEK inhibitor therapy for advance BRAF mutant melanoma. ClinicalTrials.gov. Available: https:\/\/clinicaltrials.gov\/study\/NCT03543969 [Accessed 1 May 2024]."},{"key":"2024122206361731000_14.12.e091262.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2011.03.008"},{"key":"2024122206361731000_14.12.e091262.46","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh081"},{"key":"2024122206361731000_14.12.e091262.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2024122206361731000_14.12.e091262.48","unstructured":"Common terminology criteria for adverse events (CTCAE) version 5.0. Available: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf [Accessed 5 Apr 2024]."},{"key":"2024122206361731000_14.12.e091262.49","unstructured":"EORTC quality of life questionnaires. Available: https:\/\/qol.eortc.org\/questionnaires\/ [Accessed 5 Apr 2024]."},{"key":"2024122206361731000_14.12.e091262.50","doi-asserted-by":"crossref","DOI":"10.1111\/ecc.13400","article-title":"Rapid screener for the assessment of fear of progression in cancer survivors: The Fear of progression-Questionnaire Rapid Screener","volume":"30","author":"Youssef","year":"2021","journal-title":"Eur J Cancer Care (Engl)"},{"key":"2024122206361731000_14.12.e091262.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.07.011"},{"key":"2024122206361731000_14.12.e091262.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.10.031"},{"key":"2024122206361731000_14.12.e091262.53","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e3182070f17"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-091262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T01:46:02Z","timestamp":1735004762000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-091262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":53,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,22]]},"published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1136\/bmjopen-2024-091262"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-091262","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}